Cincinnati Training Program in Pediatric Clinical and Developmental Pharmacology

辛辛那提儿科临床和发育药理学培训计划

• 批准号: 8122598
• 负责人: Alexander A Vinks
• 金额: $ 13.05万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-16 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8122598
• 关键词: Childhood; Clinical; Development; Pharmacology; Training Programs

DESCRIPTION (provided by applicant): This application for an institutional National Research Service Award (T32) in Pediatric Clinical and Developmental Pharmacology requests support for a new postdoctoral training program that will train the next generation of pediatric clinical investigators to assume leadership roles in developing innovative, high impact clinical and developmental pharmacology related approaches that will improve proper use of medicines in children to enhance pediatric therapeutics and related health outcomes of children. Many medicines used in children have not been scientifically evaluated for use in the pediatric population and are either used unlicensed or in an off-label manner. In addition, few medicines are developed specifically to treat childhood diseases. The Pediatric Clinical and Developmental Pharmacology Research Training Program (PCDP-RTP) at Cincinnati Children's Hospital Medical Center (CCHMC) is designed specifically to address this critical need. The program is based in the Division of Pediatric Clinical Pharmacology, which is jointly a unit within the Department of Pediatrics and in the University of Cincinnati, College of Medicine. This T32 Pediatric Clinical and Developmental Pharmacology Research Training Program also involves strong collaborations with the James L. Winkle College of Pharmacy and the Departments of Pharmacology & Cell Biophysics and Mathematical Sciences at the University of Cincinnati. Faculty advisors for the PCDP-RTP come from 12 divisions within the Department of Pediatrics and four Departments at the University of Cincinnati. Faculty have expertise in an array of fields relevant to clinical, translational and basic science research of pediatric disease areas that include adherence, bioinformatics, biomarker development, biostatistics and epidemiology, comparative effectiveness, clinical outcomes, clinical trials, epidemiology, genetics/genomics and gene expression, clinical and developmental pharmacology, quality improvement, and systems biology/pharmacology. The T32 training program is innovative and well aligned with the objectives outlined in the program announcement because: 1) it has a focus in early and later phase studies in multiple and diverse pediatric populations through ongoing research collaborations with all major pediatric subspecialties; 2) involves the application and development of innovative quantitative methodologies such as physiologically based PK/PD modeling and simulation and disease progression analysis through our multidisciplinary Pharmacometrics Core; 3) is embedded in the institutional and Academic Health Center's pharmacogenetic/genomics research endeavors through the Personalized Medicine and Genetic Pharmacology Programs; 4) is closely integrated with biostatistics and epidemiology, bio-informatics, and health services and outcomes research; 5) can rely on over ten years of experience as one of 13 sites of the NICHD Pediatric Pharmacology Research Unit Network. The typical period of support for trainees will be two years, though an additional period of support may be provided, especially if it will make them more competitive for subsequently establishing an independent research career. The PCDP-RTP is well supported by core facilities and a variety of academic programs at the University of Cincinnati's Academic Health Center, which includes CCHMC, UCCOM, the James L. Winkle College of Pharmacy and several other allied colleges. We believe that the PCDP-RTP provides a unique resource that will open an important new avenue to enlarge the pool of talented young clinical investigators with a career interest in pediatric therapeutics. The proposed training program will allow them to acquire a refined vision for applying state of the art principles of clinical and developmental pharmacology to sound clinical research and evidence-based clinical practice to improve pediatric health outcomes. PUBLIC HEALTH RELEVANCE: The T32 Pediatric Clinical and Developmental Research Training Program will provide an outstanding resource for expanding and improving the current critically small pool of pediatric clinical pharmacologists by training the next generation of pediatric clinical investigators to assume leadership roles in developing innovative, high impact clinical and developmental pharmacology related approaches that will improve proper use of medicines in children. This will allow the further enhancement of personalized pediatric therapeutics and ultimately improve the quality of care and related health outcomes of children.

描述（由申请人提供）：该机构国家研究服务奖（T32）的儿科临床和发育药理学要求支持新的博士后培训计划的支持，该计划将培训下一代的儿科临床研究人员在开发创新的，高影响临床和发展相关的药物方面，以提高药物治疗方面的儿童的领导角色，以提高医学疗法，以增强医学上的健康状况 孩子们。尚未对儿童中使用的许多药物进行科学评估，以用于小儿人群中，并且未经许可或以外的方式使用。此外，很少有专门用于治疗儿童疾病的药物。辛辛那提儿童医院医疗中心（CCHMC）的小儿临床和发育药理学研究培训计划（PCDP-RTP）专门针对这一关键需求。该计划基于儿科临床药理学系，该药理学是在儿科系和辛辛那提大学医学院共同的一个单位。这项T32小儿临床和发育药理学研究培训计划还涉及与辛辛那提大学的药理学与细胞生物物理学和数学科学系的詹姆斯·韦克尔学院的强有力合作。 PCDP-RTP的教师顾问来自辛辛那提大学儿科和四个系的12个部门。教师在与儿科疾病领域有关的一系列领域具有专业知识，包括依从性，生物信息学，生物标志物发展，生物统计学和比较流行病学，临床成果，临床临床学，临床试验，遗传学学/遗传学/遗传学表达和临床学，临床学和临床学，临床学和发展学，临床试验，临床试验，临床学和发展。 T32培训计划具有创新性，并且与计划公告中概述的目标保持一致，因为：1）通过与所有主要的儿科诊断的持续研究合作，它在早期和后期的研究中重点是对多种和多样化的儿科人群进行的研究； 2）涉及通过我们的多学科药物计量学核心核心核心的诸如基于生理的PK/PD建模以及仿真和疾病进展分析的创新定量方法的应用和开发； 3）通过个性化医学和遗传药理学计划，嵌入了机构和学术健康中心的药物遗传学/基因组学研究中； 4）与生物统计学和流行病学，生物信息学以及卫生服务和结果研究紧密融合； 5）可以依靠十多年的经验作为NICHD小儿药理学研究单元网络的13个地点之一。尽管可以提供额外的支持时期，但对学员的典型支持时期将是两年，尤其是如果这会使他们随后建立独立的研究职业更具竞争力。辛辛那提大学的学术健康中心（包括CCHMC，UCCOM，James L. Winkle College of Pharmacy of Pharmacy of Pharmacy of Pharmacy of Phince College of Concdp-RTP）得到了核心设施和各种学术课程的良好支持。我们认为，PCDP-RTP提供了一种独特的资源，该资源将开辟一个重要的新途径，以扩大对小儿治疗剂的职业兴趣的才华横溢的年轻临床研究人员。拟议的培训计划将使他们能够获得精致的愿景，以将临床和发育药理学的最先进原则应用于临床研究和基于证据的临床实践，以改善小儿健康成果。 公共卫生相关性：T32小儿临床和发展研究培训计划将通过培训培训下一代儿科临床研究人员在开发创新，高影响临床和发展药理学相关的药物相关使用方法中，可以改善适当使用药物的儿童的儿科临床研究人员，从而为扩大和改善当前严重的小儿临床药理学家提供出色的资源。这将允许进一​​步增强个性化的儿科治疗剂，并最终提高儿童的护理质量和相关的健康成果。